$53.69
6.19% yesterday
Nasdaq, Nov 06, 10:00 pm CET

Lantheus Holdings Inc Stock price

$53.69
+0.99 1.88% 1M
-51.15 48.79% 6M
-35.77 39.98% YTD
-37.48 41.11% 1Y
-2.59 4.60% 3Y
+42.42 376.40% 5Y
+49.24 1,106.52% 10Y
+46.92 693.06% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
-3.54 6.19%

New AI Insights on Lantheus Holdings Inc Insights AI Insights on Lantheus Holdings Inc

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$3.7b
Enterprise Value
$3.5b
Net debt
positive
Cash
$695.6m
Shares outstanding
68.0m
Valuation (TTM | estimate)
P/E
13.9 | 9.4
P/S
2.4 | 2.4
EV/Sales
2.3 | 2.3
EV/FCF
7.4
P/B
3.1
Financial Health
Equity Ratio
54.9%
Return on Equity
28.7%
ROCE
23.8%
ROIC
23.5%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$1.5b | $1.5b
EBITDA
$498.9m | $569.8m
EBIT
$437.6m | $552.3m
Net Income
$271.0m | $390.3m
Free Cash Flow
$478.6m
Growth (TTM | estimate)
Revenue
5.8% | -1.4%
EBITDA
-2.7% | 11.0%
EBIT
-3.4% | 23.1%
Net Income
-36.8% | 24.9%
Free Cash Flow
48.8%
Margin (TTM | estimate)
Gross
63.8%
EBITDA
32.8% | 37.7%
EBIT
28.8%
Net
17.8% | 25.8%
Free Cash Flow
31.5%
More
EPS
$3.9
FCF per Share
$7.0
Short interest
15.2%
Employees
808
Rev per Employee
$1.9m
Show more

Is Lantheus Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Lantheus Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Lantheus Holdings Inc forecast:

15x Buy
79%
4x Hold
21%

Analyst Opinions

19 Analysts have issued a Lantheus Holdings Inc forecast:

Buy
79%
Hold
21%

Financial data from Lantheus Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,521 1,521
6% 6%
100%
- Direct Costs 551 551
8% 8%
36%
969 969
5% 5%
64%
- Selling and Administrative Expenses 393 393
17% 17%
26%
- Research and Development Expense 141 141
1% 1%
9%
499 499
3% 3%
33%
- Depreciation and Amortization 61 61
2% 2%
4%
EBIT (Operating Income) EBIT 438 438
3% 3%
29%
Net Profit 271 271
37% 37%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Lantheus Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lantheus Holdings Inc Stock News

Neutral
PRNewsWire
about 6 hours ago
LOS ANGELES , Nov. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus " or "the Company") (NASDAQ: LNTH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of LNTH during the...
Neutral
Seeking Alpha
about 14 hours ago
Lantheus Holdings, Inc. ( LNTH ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Mark Kinarney - Vice President of Investor Relations Brian Markison - CEO & Director Robert Marshall - CFO & Treasurer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Richard Newitter - Truist Securities, Inc., Research Division Matthew Taylor - Je...
Neutral
PRNewsWire
about 20 hours ago
LOS ANGELES , Nov. 6, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) have opportunity to lead the securities fraud class action lawsuit.
More Lantheus Holdings Inc News

Company Profile

Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.

Head office United States
CEO Brian Markison
Employees 808
Founded 1956
Website www.lantheus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today